WP12 – Building an ever-warm European clinical research network
When an infectious disease emergency occurs, clinical research must start quickly. However, research networks, hospitals, primary care sites, cohorts and trial infrastructures are often organised separately, operate under different procedures and are not always ready to work together at short notice.
WP12 aims to address this challenge by establishing an Ever-Warm EU-wide Network of Networks for Clinical Research, or EWNN.
The EWNN will connect and coordinate existing clinical research networks across Europe so that they remain active, prepared and able to mobilise rapidly when a new infectious disease threat emerges. Rather than creating a single new network, it will build on existing capacities, strengthen cooperation between them and address the gaps that could limit Europe’s ability to launch coordinated clinical studies during a crisis.
On this page
Building a network that is ready before a crisis
The EWNN will operate during both interepidemic and epidemic periods. Between crises, its members will work together to develop shared approaches, test operational procedures and maintain the relationships and capacities needed for rapid activation.
WP12 will define the scope and structure of the EWNN, the level of activity required to keep it operational, and the criteria for including research networks and clinical study sites. It will also develop the governance and coordination mechanisms needed to ensure that the network functions effectively within BE READY and alongside other European initiatives.
Connecting clinical research capacities across Europe
The EWNN will bring together different parts of the clinical research ecosystem, including hospitals, primary care networks, vaccine trial sites, cohorts and other research groups involved in studies of treatments, vaccines and infectious diseases.
WP12 will map existing networks and sites, assess their capacities and identify important gaps. These may include:
- countries or regions with limited research capacity
- underrepresented patient populations
- insufficient expertise for particular diseases
- a lack of sites able to conduct specific types of studies.
This work will help BE READY identify where additional capacities, sites or partnerships are needed to ensure that the network is inclusive, geographically balanced and able to respond to a wide range of threats.
Developing shared standards and ways of working
Rapid research activation requires more than connected sites. Networks must also be able to work according to compatible scientific, methodological and operational approaches.
WP12 will therefore support the development of common criteria, quality standards and coordination processes. It will create scientific forums where experts from different networks can share experience, develop common methodologies and address challenges affecting observational studies and clinical trials.
These activities will be closely coordinated with other BE READY Work Packages, particularly those working on research priorities, infrastructures, data, regulation, ethics, training and capacity building.
Testing operational readiness
A key component of WP12 will be the implementation of a pilot clinical study during the interepidemic period.
The purpose of this study will not only be to answer a scientific question, but also to test how effectively the EWNN can operate in practice. It will help assess whether participating networks and sites can coordinate, activate procedures, recruit participants, collect and share data and conduct a study across countries.
The lessons learned will be used to improve the network and ensure that it can be activated more rapidly and efficiently during a future epidemic or pandemic.
A long-term resource for European preparedness
By maintaining cooperation and scientific activity between crises, the EWNN will help prevent clinical research capacities from becoming fragmented or inactive.
Its long-term ambition is to provide Europe with a coordinated and sustainable clinical research ecosystem that can rapidly generate reliable evidence on diagnostics, vaccines, treatments and other interventions when a new infectious disease threat emerges.